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Abstract
This study aims to investigate apoptosis induced by lexatumumab (Lexa) in hepatocellular carcinoma (HCC) cells. We assessed
the sensitivity of HCC cell lines and normal human hepatocytes to Lexa and explored the sensitization of HCC cells to Lexa-
induced apoptosis by cycloheximide (CHX). Our data indicated that CHX sensitized HCC cell lines to Lexa-induced apoptosis,
whereas treatment using solely CHX or Lexa was ineffective. The sequential treatment of CHX followed by Lexa dramatically
induced caspase-dependent apoptosis in HCC cells and had synergistically increased intracellular rates of reactive oxygen
species (ROS). Additionally, when ROS production was blocked by N-acetyl-L-cysteine (NAC), HCC cells were protected against
Lexa and CHXcombination treatment-inducedapoptosis.ROSgeneration induced bycombination treatmentofLexaand CHX
triggered pro-apoptotic protein Bax oligomerization, conformation change, and translocation to mitochondria, which resulted
in the release of cytochrome c and subsequent cell death. Furthermore, HSP90 was involved in mediating Lexa and CHX
combination treatment-induced ROS increase and apoptotic death. More importantly, we observed that combination
treatment of Lexa and CHX did not cause apoptotic toxicity in normal human primary hepatocytes. These results suggest that
Lexa and CHX combination treatment merits investigation for the development of therapies for patients with HCC.
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Introduction
Hepatocellular cancer is one of the five most common cancers
worldwide and is fatal in more than 90% of patients [1]. Currently,
there are no effective therapies for liver cancer other than surgical
resection or liver transplantation in the early stages of tumor
development. Such treatments only apply to a small percentage of
patients, while the majority die within 6 months of diagnosis [2].
Therefore, new therapeutic strategies are urgently needed.
Targeting death receptor activation-mediated cell death is
quickly becoming one of the most promising strategies for anti-
cancer therapy [3,4]. An overwhelming number of studies have
demonstrated that the administration of death receptor agonists
can selectively induce apoptosis in tumor cells and significantly
inhibit xenograft human tumor growth [5–8]. Among the death
receptor agonists, lexatumumab (Lexa) was developed as a
potential humanized anti-death receptor 5 (DR5) monoclonal
antibody. It has been shown that Lexa specifically binds to death
receptor 5 and induces apoptosis in a number of tumor cell lines,
including renal cell carcinoma (RCC) [9], human myeloma cell
lines (HMCL) [10], and malignant pleural mesothelioma (MPM)
[11]. Different researchers have also reported that combination
treatment with agonistic death receptor 5 mAbs and chemother-
apeutic drugs exert a synergistic apoptotic effect in some tumor cell
lines, such as lymphoma [12–14], breast cancer [15], colorectal
cancer [16], and malignant mesothelioma [11]. Nevertheless, it
remains unknown whether Lexa can induce apoptosis in
hepatocellular carcinoma (HCC) cells or whether it has apoptotic
toxicity to normal hepatocytes.
In the present study, we are the first to show data indicating that
Lexa can significantly induce apoptosis in resistant HCC cell lines
in the presence of cycloheximide (CHX). We provide evidence to
demonstrate that treatment combining Lexa and CHX induces
caspase-dependent apoptosis in HCC cells. Intracellular reactive
oxygen species (ROS) generation, Bax/Bak activation, and heat
shock protein 90 (HSP90) inactivation are involved in killing the
HCC cells. More importantly, we found that Lexa and CHX
combination treatment has no apparent apoptotic toxicity to
normal human hepatocytes.
Materials and Methods
Cell culture and reagents
Human hepatocellular carcinoma cell lines, Huh7 and LH86
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM)
with 10% fetal bovine serum (Sigma, St. Louis, MO) and
antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) at
37uCi n5 %C O 2. Normal primary human hepatocytes were
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cultured in DMEM/F12 (1:1) culture medium. The human
normal hepatocytes used were at least 90% viable before
treatment. Anti-caspase 8, anti-caspase 10, anti-caspase 3, anti-
cytochrome c, anti-HSP90, anti-Bcl-xL, anti-IKK-b, anti-IkB-a,
anti-p-IkB-a, anti-Mcl-1, anti-Bak, anti-DR4, anti-DR5, and anti-
Bid primary antibodies were obtained from Cell Signaling
Technology(Beverly, MA); Dihydroethidium (DHED), N-acetyl-
L-cysteine (NAC), Bis (maleimido) hexane (BMH)/DSS, DMAG-
17, Mito Tracker (Red) CMXRos, IKK inhibitor, NEMO-binding
domain peptide (NBD): MAPK inhibitor: PD98059, P38 inhibitor:
SB203580, and JNK inhibitor: SP600125 were obtained from
Invitrogen (Carlsbad, CA); anti-b-actin, anti-Bax 6A7 monoclonal
antibodies, Hoechst 33258, and 49,6 9-Diamidino-2-phenylindole
(DAPI) were obtained from Sigma (St. Louis, MO); z-IETD-FMK
and z-VAD-FMK were obtained from Calbiochem (San Diego,
CA). Anti-Bax (N-20) primary polyclonal antibody, goat anti-
rabbit horseradish peroxidase (HRP) conjugated secondary
antibody, Goat anti-rabbit secondary antibody conjugated with
FITC, and protein G plus-agarose were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). The Annexin-V apoptosis
detection kit was obtained from BD Bioscience (San Diego, CA).
Lexatumumab was kindly provided by Human Genome Science
Inc. [12,17].
Hoechst staining assay
Apoptosis was determined through nuclear morphology change.
After treatment with different stimuli, cells were stained with
Hoechst 33258 at 37uC for 10 min. Cellular DNA fragmentation/
nucleus condensation was detected using an Olympus fluorescent
microscope. Apoptotic cell death ratio was assessed through
calculating the number of apoptotic cells with condensed nuclei in
six to eight randomly selected areas.
DNA ladder assay
A DNA ladder assay was performed as previously described [18]
with modification. Briefly, cells treated under different conditions
were harvested and washed with 16phosphate buffered saline
(PBS). Cell pellets were resuspended with lysis buffer (1% NP-40 in
20 mM EDTA, 50 mM Tris-HCl, pH 7.5). The samples were
centrifuged at 1,6006g for 5 min and supernatants were
transferred to new tubes. SDS (final concentration 1%) and
RNase A (final concentration 5 mg/ml) were added to the
supernatants, and the mixture was incubated at 56uC for 2 h.
After addition of proteinase K (final concentration 2.5 mg/ml), the
samples were incubated at 37uC for 2 h. DNA was precipitated
with the addition of 10 M ammonium acetate and ethanol,
washed once with 70% ethanol and then dissolved in water and
separated by electrophoresis in 1% agarose gel.
Fluorescence assisted cell sorting (FACS) assay
Apoptosis was measured using the Annexin-V detection kit
according to the manufacturer’s instructions. Flow cytometric
analysis was performed to monitor the green fluorescence of the
FITC-conjugated Annexin-V and the red fluorescence of DNA-
bound propidium iodide (PI). All data were analyzed with a Cell
Quest software (BD).
Western blotting analysis
Cells were harvested and washed twice with 16PBS. The cell
pellets were resuspended in lysis buffer containing Nonidet P-40
(10 mM HEPES, pH 7.4, 2 mM EGTA, 0.5% Nonidet P-40,
1 mM NaF, 1 mM NaVO4, 1 mM phenylmethylsulfonyl fluoride,
1 mM dithiothreitol, 50 mg/ml trypsin inhibitor, 10 mg/ml
aprotinin, and leupeptin) and incubated on ice for 30 min. After
centrifugation at 12,0006g at 4uC for 15 min, the supernatant was
transferred to a new tube and the protein concentration was
determined. Equivalent samples (20 mg of protein) were subjected
to SDS-PAGE on 12% gels. The proteins were transferred to
nitrocellulose membranes and probed with the indicated primary
antibodies, followed by the appropriate secondary antibodies
conjugated with horseradish peroxidase. Immunoreactive bands
were detected using enhanced chemiluminescence (ECL) (Pierce,
Rockford, IL). The molecular sizes of the proteins detected were
determined by comparison with prestained protein markers (Bio-
Rad, Hercules, CA).
Immuno-fluoresence staining
Immunostaining was performed as described previously [19]
with modification. Briefly, cells seeded on cover-slips in culture
dishes were treated with Lexa in the presence of CHX for 6 h.
Mito-Tracker (Red) was directly added to cultures and incubated
for 15 min. Cells were washed with 16 PBS, fixed with 3.7%
paraformaldehyde (PFA) at 37uC for 15 min, and then quenched
with 50 mM NH4Cl. After washing with PBS twice, cells were
permeabilized with 0.2% Triton X-100 in PBS, then blocked with
PBS containing 5% goat serum for 30 min. Cells were further
incubated with primary antibody cytochrome c overnight at 4uC,
followed by staining with FITC conjugated goat anti-rabbit IgG
(1:200) for 2 h at room temperature. The cover-slips were then
extensively washed and mounted in Mowiol with DAPI dye.
Fluorescent images were obtained using an Olympus fluorescent
microscope.
Bax cross-linking
In vitro protein cross-linking was carried out as previously
described [20] with minor modification. Cells treated with
different conditions were harvested. Cell lysates were prepared
after lysis with HEPES-CHAPS lysis buffer (20 mM HEPES
pH 7.2, 150 mM NaCl, 2 mM EDTA, 10 mM glucose, 2%
CHAPS). Bis (maleimido) hexane (BMH) substrate or dimethyl
sulfoxide (DMSO) was added at a final concentration of 2 mM.
The samples were incubated at room temperature for 30 min and
quenched by the addition of 1 M Tris-HCl (pH 7.5). An in vivo
protein cross linking assay was performed as previously described.
Following treatments with Lexa or Lexa combined with CHX,
cells were washed with conjugating buffer containing 150 mM
NaCl, 20 mM HEPES (pH 7.2), 1.5 mM MgCl2, and 10 mM
glucose. DSS in DMSO was added for a final concentration of
2 mM. After reaction at room temperature for 30 min, the cross-
linker was quenched by the addition of 1 M Tris-HCl (pH 7.5) for
a final concentration of 20 mM. Samples were then solubilized in
1% NP-40 and centrifuged at 12,0006g for 10 min. A 20-ml
aliquot from the 400 ml cross-linked lysate was analyzed by
Western blotting with Bax (N-20) polyclonal antibody.
ROS detection
The intracellular production of ROS was measured by
fluorogenic probe dihydroethidium-(DHED) based fluorescent
staining. Briefly, after various treatments, cells were incubated
with DHED (5 mM) for 30 min at 37uC, then rapidly rinsed twice
with 16PBS and observed under fluorescent microscope.
siRNA knockdown
siRNA knockdown was performed as previously described [21].
Smart-pool pre-designed siRNA duplexes targeted against human
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PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e16966Figure 1. Lexa and CHX combination treatment induces apoptosis in HCC cells. A, Huh7 cells were treated with TNF-a (10 ng/ml) or Lexa
(1 mg/ml) for indicated times. Cell lysates were prepared and subjected to Western blotting to detect the expression of IkB-a and phospho-IkB-a. b-
actin protein levels were used as an equal protein loading control (Lexa, lexatumumab). B, Huh7 cells were treated with DMSO (Con), CHX (10 mg/ml),
Lexa (1 mg/ml), or a combination of Lexa (1 mg/ml) and CHX (10 mg/ml). Apoptosis was measured by nuclear dye Hoechst 33258 staining to label DNA
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MA). HCC cells were plated at a density of 1610
6 cells/well in 6-
well plates (BD Bioscience, San Diego, CA). Next day, cells were
transfected with 100 nM siRNA duplex mixtures for 24 h in the
presence of lipo-fectamine RNAiMax (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. A non-specific
random siRNA (Cell Signaling Biotechnology, Beverly, MA) was
also transfected at the same concentration as control.
Subcellular fractionation
This assay was performed as described previously [22]. Cells
were harvested and resuspended in three volumes of hypotonic
buffer (210 mM sucrose, 70 mM mannitol, 10 mM HEPES
(pH 7.4), 1 mM EDTA) containing 1 mM phenylmethylsulfonyl
fluoride (PMSF), 50 mg/ml trypsin inhibitor, 10 mg/ml leupeptin,
5 mg/ml aprotinin, and 10 mg/ml pepstatin. After gentle homog-
enization with a Dounce homogenizer, cell lysates were centri-
fuged at 10006g for 5 min to remove unbroken cells and nuclei.
The postnuclear supernatant was centrifuged at 10,0006g to pellet
the mitochondria-enriched heavy membrane fraction. The
supernatant was further centrifuged at 100,0006g to obtain the
cytosolic fraction. A 30-ml aliquot from the 500 ml cytosolic
fraction was analyzed by Western blotting with anti-cytochrome c
monoclonal antibody.
Detection of Bax conformation change
This assays was performed as described previously [23]. Cells
were lysed with Chaps lysis buffer (10 mM HEPES (pH 7.4),
150 mM NaCl, and 1% Chaps) containing 1 mM phenylmethyl-
sulfonyl fluoride (PMSF), 50 mg/ml trypsin inhibitor, 10 mg/ml
leupeptin, 1 mg/ml aprotinin, and 5 mg/ml pepstatin. The cell
lysates were normalized for protein content and 500 mg of total
protein was incubated with 2 mg of anti-Bax 6A7 monoclonal
antibody in 500 ml of Chaps lysis buffer at 4uC for 4 h. Then,
40 ml of protein G plus-agarose were added into the reactions and
incubated at 4uC for an additional 2 h. Following three washings
in Chaps lysis buffer, beads were boiled in loading buffer, and the
conformationally changed Bax protein in the immunoprecipitates
was subjected to SDS–PAGE (15% gel) and immunoblot analysis
with anti-Bax polyclonal antibody as described above.
Results
Lexa induces apoptosis in HCC cells in the presence of
CHX
Increasing evidence indicated that many cancer types including
breast cancer cells, lung cancer cells, and hepatoma cells, could
develop resistance to TRAIL-induced apoptosis through DR5-
mediated activation of NF-kB signal pathway [24–26]. Here, to
investigate whether Lexa triggers NF-kB activation in HCC cell
lines, Huh7 cells were treated with TNF-a or Lexa for the
indicated times. Western blotting results indicated that TNF-a
induced Ik-B-a decrease after treatment for 15 min and Lexa did
that with treatment for 60 min. However, compared with TNF-a,
Lexa could not promote Ik-B-a phosphorylation at 60 min
(Fig. 1A); thus Lexa, a DR5 specific monoclonal antibody unlike
multifunctional TNF-a, did not activate the anti-apoptotic NF-kB
signal pathway through binding to DR5. Then, we tested whether
HCC cells are sensitive to Lexa-induced cell death. Huh7 and
LH86 cells were treated with Lexa (1 mg/ml) for up to 6 h.
Apoptosis assays indicated that both HCC cell lines were resistant
to Lexa (see Lexa-treated groups in Fig. 1B, 1C, and 1D for Huh7
cells, and Fig. 1E and 1F for LH86 cells).
It has been shown that chemotherapeutic reagent CHX, a
protein synthesis inhibitor, can enhance TRAIL-induced apoptosis
in tumor cells such as renal cancer [27], colon cancer [28], and
lung carcinoma [29]. As cells did not undergo apoptosis with Lexa
single treatment, we examined whether CHX can alter the
insensitivity of HCC cells to Lexa. Apoptosis assays indicated that
pre-treatment with CHX (10 mg/ml for 30 min) followed by Lexa
(1 mg/ml for 6 h) could significantly enhance apoptosis induction
in both Huh7 and LH86 cells (Lexa and CHX combination
treated groups in Fig. 1B, 1C, and 1D for Huh7 cells, and Fig. 1E
and 1F for LH86 cells). To further confirm Lexa-induced
apoptosis could be enhanced by CHX pre-treatment, we evaluated
caspase activation and the cleavage of the pro-apoptotic protein
Bid through Western blotting analysis. Our data indicated that co-
treatment with Lexa and CHX for 6 h significantly induced
proteolytic processing of caspase 8, 10, and 3, as well as Bid
(Fig. 1G, right panel), but single treatment with either Lexa or
CHX could not result in cleaved bands or active subunits from
procaspase 8, procaspase 10, or procaspase 3. Additionally, Bid
cleavage was not progressively processed after 3 h (Fig. 1G, left
panel), supporting the assumption that these liver cancer cells are
resistant to Lexa-induced apoptosis. To investigate the possible
signaling pathways underlying the resistance of HCC cells to Lexa,
we used the specific inhibitors NBD, PD98059, SB203580, and
SP600125 to respectively inhibit the IKK, MAPK, P38, and JNK
signaling pathways. As shown in Fig. 1H, in comparison with
positive control that CHX and Lexa combination treatment-
induced caspase 3 cleavages, the other four inhibitors did not
reverse the insensitivity of HCC cells to Lexa-induced apoptosis.
These results suggest that Lexa and CHX combination treatment
synergistically induces apoptosis in HCC cells.
Lexa and CHX combination treatment induces caspase
dependent apoptosis
Death receptor-mediated apoptosis can be classified as either
caspase dependent or caspase independent [30,31]. To examine
whether Lexa and CHX combination-induced apoptosis is
fragmentation (nuclear morphology changes). (Apoptotic cells were marked with arrows). C, Huh7 cells were treated with DMSO (Con), CHX (10 mg/
ml), Lexa (1 mg/ml), or combination treatment of Lexa (1 mg/ml) and CHX (10 mg/ml) and apoptosis was evaluated through Annexin V and PI double
staining based FACS analysis using the Annexin-V assay kit (see ’materials and methods’). D, The percentage of apoptotic cells were characterized as
those that stained with Annexin-V. Data represent the mean values of three independent experiments (*p,0.05). E, LH86 cells were treated with
DMSO (Con), CHX (10 mg/ml), Lexa (1 mg/ml), or a combination of Lexa (1 mg/ml) and CHX (10 mg/ml). Apoptosis was measured as in Fig. 1B
(Apoptotic cells were marked with arrows). F, LH86 cells were treated with various stimuli as in Fig. 1E. Apoptosis was measured through FACS
analysis as in Fig. 1C and 1D and statistical analysis was performed to show percentage of Annexin-V positive cells for apoptosis ratio. Data represent
the mean values of three independent experiments (**p,0.05). G, Huh7 cells were treated with Lexa (1 mg/ml) or combination of Lexa (1 mg/ml) and
CHX (10 mg/ml) for up to 6 h and harvested. Cell lysates were prepared for Western blotting to detect the cleavages of caspase 8, caspase 10, caspase
3, and Bid. b-actin protein levels were set up as loading control for equal total protein amounts. H, Huh7 cells treated with indicated conditions for
6 h were harvested and cell lysates were prepared and subjected to Western blotting analysis. Caspase 3 activation was evaluated through detecting
cleaved bands with specific antibody. b-actin protein levels were set up as loading control for equal total protein amounts. Each experiment was
conducted in triplicate or duplicate and repeated twice independently.
doi:10.1371/journal.pone.0016966.g001
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with pan-caspase inhibitor z-VAD-FMK (50 mM) for 1 h, followed
by various stimuli as indicated. DNA ladder assays (Fig. 2A), DNA
fragmentation analysis (Fig. 2B and 2C) and FACS analysis
(Fig. 2D and 2E) demonstrated that apoptosis induced by
combination treatment with Lexa and CHX were totally blocked
by pan-caspase inhibitor z-VAD-FMK, suggesting that CHX-
sensitized and Lexa-induced apoptosis is caspase dependent.
Meanwhile, we measured the effects of caspase 8 specific inhibitor
z-IETD-FMK on apoptosis induced by Lexa and CHX combi-
nation treatment. As shown in Fig. 2A, 2B, 2C, 2D, and 2E,
blockade of caspase 8 activation completely abolished Lexa and
CHX combination-induced apoptosis in Huh7 cells. Taken
together, these results suggest that caspase activation plays a key
role in Lexa-mediated apoptosis induction in HCC cells.
Lexa and CHX combination treatment-induced apoptosis
is regulated by ROS
To assess whether ROS plays a major role in regulating Lexa
and CHX combination-induced apoptosis, HCC cells were treated
with Lexa and CHX for 6 h. Intracellular ROS levels were
determined by a DHED-based fluorescence assay. As shown in
Fig. 3A, Lexa and CHX combination treatment induced ROS
dramatic increase in apoptotic cells, but not in non-apoptotic cells,
suggesting ROS may contribute to CHX-and Lexa-induced
apoptosis. To further determine whether generation of ROS can
regulate apoptosis, N-acetyl-L-cysteine (NAC), a precursor of
reduced glutathione (GSH) widely used as a thiol-containing
antioxidant to scavenge intracellular ROS, was added before
administration of Lexa and CHX. As shown in Fig. 3B, the ROS
increase induced by combined treatment of Lexa and CHX was
completely negated. More importantly, apoptosis assays indicated
that the blockade of ROS by NAC can also protect cells against
Lexa-and CHX-induced apoptosis (Fig. 3C, 3D, 3E, and 3F).
These results suggest that Lexa and CHX combination treatment-
induced ROS increase can trigger apoptosis in HCC cells.
Effects of combination treatment with Lexa and CHX on
protein expression in HCC cells
Since CHX is a protein synthesis inhibitor, it may sensitize Lexa
to induce apoptosis through down-regulating anti-apoptotic
proteins. We analyzed the apoptosis associated protein expression
changes in HCC cells treated with Lexa alone or combination-
treated with Lexa and CHX for up to 6 h. Western blotting results
showed that there were no decreases in anti-apoptotic molecules
Bcl-xL or survivin expression; of the pro-apoptotic proteins, both
Bad and Bim were down-regulated, while Bak was down-regulated
with Lexa single treatment and up-regulated with combination
treatment. Additionally, protein levels of pro-apoptotic Bax were
not affected, and the expression levels of death receptors DR4 and
Figure 2. Lexa and CHX combination treatment induces caspase-dependent apoptosis. A, Huh7 cells were treated with different
conditions as indicated. Apoptosis was tested by DNA ladder assays as described in ‘Materials and Methods’. B, Huh7 cells were treated with various
stimuli as indicated (Lexa, (1 mg/ml), CHX, (10 mg/ml), or caspase 8 inhibitor IETD (50 mM)). Apoptotic cells were examined as described in Fig. 1B
(representative apoptotic cells were marked with arrows). C, Huh7 cells were treated with conditions as indicated and apoptotic ratio was determined
by counting cells with apoptotic nuclei as described in ‘Materials and Methods’. Data represent the mean values of three independent experiments
(*p,0.05). D, Huh7 cells were treated with various conditions as indicated (Lexa, (1 mg/ml), CHX, (10 mg/ml), IETD (50 mM), z-VAD (50 mM)). Apoptosis
was evaluated as in Fig. 1C. E, Huh7 cells were treated with different conditions as indicated and apoptosis percentage was determined as in Fig. 1D.
Data represent the mean values of three independent experiments (**p,0.05).
doi:10.1371/journal.pone.0016966.g002
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PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e16966Figure 3. Lexa and CHX combination treatment induces apoptosis via ROS. A, Huh7cells were treated with the combinationof Lexa (1 mg/ml) and
CHX (10 mg/ml). Nuclei were stained by Hoechst 33258 (right panel-blue, thin arrow marks the nucleus in non-apoptotic cells; thick arrow marks apoptotic
condensed nuclei). Intracellular ROS level was assessed by DHED-based fluorescent staining (middle panel-red, thin arrow marks ROS in non-apoptotic cells,
thick arrow marks ROS in apoptotic cells), and merged figure (left) to show that ROS levels in non-apoptotic cells are lower than that in apoptotic cells( w h i t e
boxes marked areas were enlarged (Zoom in)). B, Huh7 cells were treated with DMSO (Con), Lexa (1 mg/ml), CHX (10 mg/ml), NAC (10 mM), a combination of
Lexa (1 mg/ml) and CHX (10 mg/ml) in the absence or presence of NAC (10 mM). Intracellular ROS level was measured with DHED dye (red fluorescence). C,
Huh7 cells were treated with various stimuli as indicated and apoptosis was assessed by DNA ladder. D, Huh7 cells treated with DMSO (Con), Lexa (1 mg/ml),
CHX (10 mg/ml), NAC (10 mM), the combination of Lexa (1 mg/ml) and CHX (10 mg/ml) in the absence or the presence of NAC (10 mM) for 6 h. Then cells
were stained with Hoechst 33258 to test apoptotic cell death (representative apoptotic cells are marked with arrows). E and F, Huh7 cells were treated with
conditions as indicated. Apoptosis was evaluated as in Fig. 1C and 1D. Data represent the mean values of three independent experiments (**p,0.05).
doi:10.1371/journal.pone.0016966.g003
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that the inhibitor CHX could not completely block protein
synthesis stimulated by Lexa in HCC cells and that apoptosis
induced by combination treatment of Lexa and CHX may be
mediated by Bax/Bak activation.
Combination treatment of Lexa and CHX triggers the
activation of Bax
It is well known that under various cellular stresses, pro-
apoptotic Bax/Bak can be activated through oligomerization and
conformation change, resulting in mitochondria-dependent apop-
tosis [32–35]. Therefore, we examined whether Lexa and CHX
co-treatment can activate Bax through oligomerization in HCC
cells. Our results revealed that in the presence of CHX (10 mg/ml),
Bax dimerization was up-regulated by Lexa in HCC cells (Fig. 5A,
5B, and 5C). To further test whether ROS was involved in Bax
dimerization, cells were pre-incubated with NAC before the
addition of Lexa and CHX. As shown in Fig. 5C, pre-treatment
with NAC resulted in significant inhibition of Bax dimerization
induced by combination treatment of Lexa and CHX.
Next we attempted to test the possibility that intracellular ROS
could induce Bax to undergo conformation change in HCC cells
combination-treated with Lexa and CHX. To this end, a Bax
monoclonal antibody 6A7 that specifically recognizes conforma-
tionally changed Bax was used to do immunoprecipitation. As
shown in Fig. 5D, combination treatment of Lexa and CHX could
induce Bax conformation change in both LH86 and Huh7 HCC
cells. As expected, with the addition of antioxidants NAC to block
ROS, conformationally changed Bax was significant decreased.
After oligomerization and conformational change, the activated
Bax can translocate to mitochondria, which results in cytochrome
c release. In our study, we observed transiently transfected GFP-
Bax translocation to mitochondria in cells treated with Lexa and
CHX for 6 h (Fig. 6A). Next, we studied cytochrome c release
from mitochondria in cells with combinational treatment of Lexa
and CHX. Immunofluorescence staining results indicated that in
cells treated with Lexa and CHX, cytochrome c was released and
diffused into the cytosol (Fig. 6B, center), but this process was
blocked by NAC (Fig. 6B, right panel). These observations were
consistent with the results presented above: Lexa and CHX co-
treatment-induced apoptosis can be negated by NAC (Fig. 3C, 3D,
3E, and 3F). Meanwhile, subcellular fractionation assay also
showed Lexa and CHX combination treatment induced cyto-
chrome c release in HCC cells, whereas, NAC addition
significantly could block this process (Fig. 6C). Taken together,
these results suggest that Lexa and CHX combination treatment-
induced ROS generation results in apoptosis via the activation of
Bax.
HSP90 is involved in Lexa and CHX combination
treatment-induced ROS and apoptosis
Heat shock protein 90 (HSP90) may confer a survival advantage
to tumor cells through association with several regulators of
apoptosis [36–38]. HSP90 binding to its client protein may protect
against physiological oxidative stress [39,40]. Here, our data
demonstrated that CHX specifically decreased HSP90 protein
expression (Fig. 7A). Then, we asked whether HSP90 plays a key
role in regulating Lexa and CHX combination-induced apoptosis.
Using DMAG-17, a specific HSP90 inhibitor to block its activity,
we observed that HSP90 inhibition significantly enhanced Lexa
treatment-induced apoptotic cell death (Fig. 7B and 7D) and ROS
production (Fig. 7C and 7D) in HCC cells, suggesting HSP90 may
be involved in Lexa-induced ROS generation. It has also been
reported that DMAG-17 can induce apoptosis in tumor cells
through down-regulating IKKs, Mcl-1, and survivin expression
[41]. However, in this study, apoptosis assays indicated that HCC
cells are insensitive to DMAG-17 single treatment (Fig.7B and
7D). Further Western blotting results showed that protein levels of
IKK-b were decreased; IkB-a and the NF-kB targeted proteins
survivin were increased; Mcl-1, another anti-apoptotic protein,
was not affected by DMAG-17 treatment (Fig. 7E). Finally, to
further confirm that HSP90 inactivation is critical for Lexa-
induced apoptosis, HCC cells were transiently transfected with
HSP90 specific siRNA to knockdown HSP90 expression and were
treated with Lexa. Apoptosis assays indicated that HSP90
knockdown (Fig. 7F) significantly sensitized Lexa-induced apop-
tosis in HCC cells (Fig. 7G, and 7H). These results suggest that
HSP90 can be targeted by CHX to regulate cell sensitivity to
Lexa-induced apoptosis.
Lexa and CHX combination treatment has no apoptotic
effects on normal human hepatocytes
A major barrier for the clinical use of TNF-a or TRAIL is their
potential toxicity to normal human cells [42–45]. In this study, we
examined whether Lexa and CHX combination treatment can
selectively induce apoptosis in HCC cells. As shown in Fig. 8A,
combination treatment with Lexa (1 mg/ml) and CHX (10 mg/ml)
induced caspase 8 activation in HCC cells, but not in normal
human hepatocytes. To further evaluate why normal hepatocytes
are insensitive to CHX and Lexa co-treatment, we examined the
expression of anti-apoptotic and pro-apoptotic proteins in HCC
cells and normal human hepatocytes. In comparison with HCC
cells, levels of pro-apoptotic Bax and Bak were undetectable in
normal human hepatocytes, anti-apoptotic Bcl-xL levels were
Figure 4. Protein expression in HCC cells treated with Lexa or
the combination of Lexa and CHX. LH86 cells were treated with
Lexa (1 mg/ml) or pre-treated with CHX (10 mg/ml) followed by Lexa
(1 mg/ml) for up to 6 h. Cells were harvested and cell lysates were
prepared for Western blotting. Bcl-xL, survivin, Bim, Bad, Bak, Bax, DR4,
and DR5 were detected with specific antibodies respectively. b-actin
was detected with anti-b-actin mouse antibody for an equal protein
loading control.
doi:10.1371/journal.pone.0016966.g004
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much higher in HCC cells than those in normal human
hepatocytes. However, DR5 protein in normal human hepatocytes
showed much greater expression compared with that in HCC cells
(Fig. 8B). These observations suggest that the insensitivity of
human normal liver cells to Lexa and CHX combination
treatment is not controlled by death receptor 5 (DR5) expression
level on the cellular membrane, but rather determined by the
expression levels of intracellular pro-apoptotic proteins, including
Bax, Bak, and Bid. Taken together, these results suggest that CHX
can selectively enhance Lexa to induce apoptosis in HCC cells.
Discussion
In the present study, we investigated apoptosis induced by
combination treatment with Lexa and CHX in resistant HCC
cells. Our results demonstrated that pre-incubation with CHX
could render resistant HCC cells sensitive to monoclonal antibody
Lexa-induced apoptosis. Lexa and CHX combination treatment-
induced apoptosis was triggered by intracellular ROS production.
ROS accumulation in cells resulted in pro-apoptotic Bax/Bak
activation through oligomerization and conformation change.
HSP90 may act as a switch controlled by CHX to regulate
intracellular ROS levels upon cell death stimulation. More
interestingly, the combination treatment did not induce apoptosis
in normal human hepatocytes comparing with the HCC cells
under identical conditions. These findings are promising for the
clinical use of CHX and Lexa as a novel chemotherapeutic option
in the treatment of patients with HCC.
Lexa, a humanized monoclonal antibody, specifically binds to
DR5 to activate death signals and has a longer half life in vivo
rendering it as a potential killer of tumor cells. Here, we used
Figure 5. Lexa and CHX co-treatment-induced ROS increase triggers Bax activation. A, LH86 cells were treated with Lexa (1 mg/ml) or pre-
treated with CHX (10 mg/ml) followed by Lexa (1 mg/ml) for up to 6 h. Cells were then treated with the cross-linking agent DSS. Bax proteins were
resolved by SDS-PAGE and detected by Western blotting using a Bax polyclonal antibody. A 23 kDa band represents Bax monomers, and bands at
46 kDa, detected only in the presence of DSS, represent Bax homodimers. Relative intensity of Bax dimer bands was analyzed by Image J software. B,
Huh7 cells were treated with a combination of Lexa (1 mg/ml) and CHX(10 mg/ml) for up to 6 h. Cell lysates were prepared and incubated with cross
linker BMH as described in Materials and Methods. Cell lysates and cross linker mixture was boiled with 16SDS loading buffer and Bax oligomerization
was analyzed by Western blotting. The Bax dimer was recognized by Bax polyclonal antibody. Relative intensity of Bax dimer bands was quantified by
Image J software. C, Huh7 cells treated with conditions as indicated and were harvested and extracts were prepared for Western blotting analysis to
analyze Bax dimer formation. Relative intensity of Bax dimer bands was qualified by Image J software. D, LH86 (right panel) or Huh 7 (left panel) cells
treated with various stimuli as indicated were harvested and lysed in Chaps lysis buffer and subjected to immunoprecipitation with anti-Bax 6A7
antibody for detection of conformationally changed Bax protein. Cell lysate obtained by NP-40 lysis was used as positive control. In addition, the total
lysates were applied directly to SDS-PAGE/Western blotting analysis with specific anti-Bax polyclonal antibody and severed as loading control.
doi:10.1371/journal.pone.0016966.g005
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Our results showed that first, compared with positive control
TNF-a,I kB-a phosphorylation could not be detected in HCC
cells after treatment with Lexa, suggesting that specific binding to
DR5 avoids activation of the NF-kB signaling pathway in HCC
cells. This differs from the other two cytokines (TNF-a and
TRAIL) that can induce activation of NF-kB to produce anti-
apoptotic signals through binding to membrane [46–48]. Never-
theless, we did observe Lexa could reduce IkB-a expression in
HCC cells, of which the significance remains to be clarified in the
future. Second, single treatment of Lexa showed no lethal toxicity
to HCC cells, which is consistent with previous studies reporting
that HCC cells are resistant to TRAIL [49–51]. Third, we
observed that pre-incubation with CHX could sensitize HCC cells
to Lexa-induced apoptosis. It is therefore likely that besides
inhibition of NF-kB, there are some other mechanisms through
which CHX can sensitize Lexa to induce apoptosis in HCC cells.
Several groups have reported that activation of DR5 could
signal non-apoptotic pathways through IKK, MAPK, P38, and
JNK signaling pathways to neutralize TRAIL-induced apoptosis
[52–54]. Our data demonstrated that specific inhibitors, including
NBD, PD98059, SB203580, and SP600125, that respectively
block the above mentioned anti-apoptotic signaling pathways,
failed to reverse the resistance of HCC cells to apoptosis induced
by Lexa, suggesting that CHX sensitizing cells to Lexa lethal
toxicity does not require blocking anti-apoptotic effects from the
activation of these signaling pathways.
As a pan-protein synthesis inhibitor, CHX may inhibit the
activity of some apoptosis associated proteins by decreasing their
expressions. However, our results demonstrated that CHX could
not completely block protein synthesis because under CHX and
Lexa co-treatment, Bak protein was significantly increased,
suggesting that Bax/Bak may be activated to result in apoptotic
cell death. As expected, our studies showed that Lexa and CHX
co-treatment induced Bax oligomerization, conformational
change, and translocation, which resulted in cytochrome c release
and apoptosis. It has been reported that Bax/Bak can be activated
by intracellular ROS to induce cell death in human colorectal
cancer cells [55,56]. Similarly in this study, when HCC cells were
co-treated with CHX and Lexa, we observed ROS increase in
apoptotic cells, but not in non-apoptotic ones. Moreover, the
blockade of ROS with NAC not only prevented Bax oligomer-
ization and conformational changes, but also decreased apoptosis
significantly. These results suggest that generation of ROS plays a
major role in CHX and Lexa co-treatment-induced apoptosis.
Our findings are in agreement with a study that reported that the
generation of ROS induced mitochondria-dependent apoptosis in
colon cancer cells through Bax activation [57].
In comparison to treatment with either agent alone, Lexa-
induced ROS accumulation occurred only in the presence of
CHX, which suggests that CHX may modify some intracellular
signaling pathway(s) or molecule(s) that act as a switch to control
Lexa to induce ROS generation Our results based on this
hypothesis indicated that pretreatment of cells with CHX
decreased HSP90 expression significantly, and HSP90 inactivation
by specific inhibitor DMAG-17 not only resulted in a Lexa-
induced ROS increase, but also sensitized Lexa-induced apoptosis.
Moreover, inhibition of HSP90 activity through gene silencing by
specific siRNA significantly sensitized Lexa-induced apoptosis.
These findings are also in agreement with a report showing that
blockade of HSP90 sensitized prostate cancer cells to TRAIL [58].
Meanwhile, we have observed that DMAG-17 single treatment
could not induce HCC cells to undergo apoptosis. Further analysis
indicated that although IKK-b was decreased by DMAG-17, the
NF-kB targeted proteins including survivin and Mcl-1 were not
down-regulated. This is in contrast to a previous study which
reported that DMAG-17 induced apoptosis in chronic lympho-
cytic leukemia (CLL) cells by decreasing NF-kB targeted gene
transcription [59].
In order to bring the death receptor agonists closer to clinical
therapy, we evaluated the safety of CHX and Lexa combination
treatment in normal human hepatocytes. Our data indicated that
normal human hepatocytes are resistant to this combination
treatment. Comparison of DR5 expression levels and Lexa
Figure 6. Lexa and CHX co-treatment induces Bax translocation
and cytochrome c release in HCC cells. A, Huh7 cells were
transfected with GFP-N1-Bax plasmid (0.25 mg/ml). After 10 h post-
transfection, cells were treated with Lexa (1 mg/ml) in the presence of
CHX (10 mg/ml) or not. GFP-N1-Bax translocation (green) was observed
under fluorescent microscope. Mitochondria were stained with Mito
Tracker (red) CMXRos (con, control; mito, mitochondria). Nuclear was
stained with DAPI (blue). B, Huh7 cells cultured on cover slips were
treated with Lexa (1 mg/ml) and CHX (10 mg/ml) in the presence (right
panel) or absence (middle panel) of NAC (10 mM) for 6 h. Fluorescence
immunostaining was performed to label cytochrome c with anti-
cytochrome c primary antibody and FITC conjugated goat anti-mouse
secondary antibody (green). C, Huh7 cells were exposed to different
conditions as indicated and subjected to subcellular fractionation. Then,
the cytosolic fractions were analyzed by Western blotting with antibody
specific for cytochrome c. b-actin was detected with anti-b-actin mouse
antibody for equal protein loading control.
doi:10.1371/journal.pone.0016966.g006
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study did not reveal a consistent relationship, suggesting that Lexa
sensitivity is not dependent on death receptor expression levels and
that other intracellular mechanisms may control death signal
transduction in resistant cells. As death receptor-mediated cell
death can be regulated by Bcl-2 family BH3 only proteins, such as
Bax, Bak, and Bid. Here, we found that expression levels of the
BH3 only proteins Bax and Bak were undetectable in normal
human hepatocytes, while the HCC cells showed clear high
expression of these proteins. This obvious difference may be a key
element in protecting normal cells against the toxicity of Lexa and
CHX combination treatment. In addition, to extend the use of
Lexa to treat HCC, we tested the effects of combination of the
death receptor agonists with other chemotherapeutic reagents such
as cisplatin or doxorubicin. Our data showed that only
doxorubicin could sensitize Lexa-induced apoptosis in HCC cells
(see Figure S1 and Figure S2). The underlying mechanism remains
to be investigated.
In summary, we have found that HCC cells are generally
resistant to Lexa, and CHX can sensitize HCC cells to Lexa-
Figure 7. HSP90 is involved in Lexa and CHX co-treatment-induced ROS increase and apoptosis. A, Huh7 cells were treated with CHX
(10 mg/ml) or not. Cell lysates were prepared for Western blotting. Anti-HSP90, anti-Bax, anti-Bcl-xL polyclonal antibodies were used to detect HSP90,
Bax and Bcl-xL protein levels respectively. b-actin was used as an equal protein loading control. Relative intensities of bands in Fig. 7A were analyzed
by Image J software. B, Huh7 cells were treated with DMSO (Con), Lexa (1 mg/ml), CHX (10 mg/ml), the combination of Lexa (1 mg/ml) and CHX
(10 mg/ml), DMAG (0.5 mg/ml), or the combination of Lexa (1 mg/ml) and DMAG (0.5 mg/ml) for 6 h (Cells were treated with combination of Lexa and
CHX as positive control). Apoptosis was assessed by nuclear morphological changes. C, Huh7 cells were treated as in Fig. 7B and intracellular ROS
level was detected by fluorescent staining with DFHD (Cells were treated with combination of Lexa and CHX as positive control). D, Huh7 cells were
treated with various conditions as indicated (Ctrl, control; L, Lexa (1 mg/ml); C, CHX (10 mg/ml), D, DMAG-17 (0.5 mg/ml); L+D, the combination of Lexa
(1 mg/ml) and DMAG-17 (0.5 mg/ml); L+C, the combination of Lexa (1 mg/ml) and CHX (10 mg/ml). Cells with both ROS positive and DNA
fragmentation were counted. Data represent the mean values of three independent experiments (*p,0.05; **p,0.05). E, Huh7 cells were treated
with different dosage of DMAG-17 for 24 h. Cells were harvested and cell lysates were prepared for Western blotting. IKK-b,I kB-a, survivin and Mcl-1
protein levels were detected using specific antibodies respectively. b-actin was detected by anti-b-actin mouse antibody for an equal protein loading
control. F, Huh7 cells were transfected with synthesized random siRNA (as control) and HSP90 specific siRNA, and after 48 h post-transfection cells
were subjected to Western blotting analysis with HSP90 polyclonal antibody. b-actin was used as an equal protein loading control. The intensity of
immunoblot bands Fig. 7F was analyzed by Image J software. G, Huh7 cells were transfected with synthesized random control siRNA and HSP90
siRNA, and 48 h post-transfection, cells were treated with Lexa or not and then subjected to Hoechst staining for apoptosis analysis (RC, random
siRNA control; RS+L, random siRNA cells treated with Lexa (1 mg/ml); HSC, HSP90 siRNA control; HS+L, HSP90 siRNA cells treated with Lexa (1 mg/ml)).
H, Huh7 cells treated as in Fig. 7G were harvested and subjected to Western blotting analysis with caspase 3 (for cleaved bands only) polyclonal
antibody. b-actin was detected with anti-b-actin mouse antibody for an equal protein loading control.
doi:10.1371/journal.pone.0016966.g007
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combination treatment is related to ROS generation and Bax
activation. Our study also demonstrates that normal hepatocytes
are resistant to the combination therapy. We suggest that
administration of CHX followed by Lexa should be considered
for further investigation for the treatment of patients with HCC.
Supporting Information
Figure S1 Cisplatin (Cis) could not sensitize Lexatumu-
mab (Lexa)-induced apoptosis in HCC cells. Huh7 cells
were treated with DMSO (control), Lexa (1 mg/ml), different doses
of cisplatin (1-20 mg/ml), or a combination of Lexa and cisplatin as
indicated. Apoptosis was measured by nuclear dye Hoechst 33258
staining to label DNA fragmentation (nuclear morphological
changes). Note that Lexa, cisplatin, or the combination treatment
of Lexa and cisplatin had no apoptotic toxicity to HCC cells.
(TIF)
Figure S2 Doxorubicin (Dox) sensitizes Lexatumumab
(Lexa)-induced apoptosis in HCC cells. Huh7 cells were
treated with DMSO (control), Lexa (1 mg/ml), different doses of
doxorubicin (0.25-2 mM), or a combination of Lexa and
doxorubicin as indicated. Apoptosis was measured by nuclear
dye Hoechst 33258 staining to label DNA fragmentation (nuclear
morphological changes). Note that either Lexa or doxorubicin
could not induce apoptosis in HCC cells. However, the
combination treatment of Lexa and doxorubicin induced
significant apoptosis in HCC cells.
(TIF)
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